|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Lee AW, Sze WM, Au JS, et al: Treatment
results for nasopharyngeal carcinoma in the modern era: the Hong
Kong experience. Int J Radiat Oncol Biol Phys. 61:1107–1116. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wee J, Tan EH, Tai BC, et al: Randomized
trial of radiotherapy versus concurrent chemoradiotherapy followed
by adjuvant chemotherapy in patients with American Joint Committee
on Cancer/International Union against cancer stage III and IV
nasopharyngeal cancer of the endemic variety. J Clin Oncol.
23:6730–6738. 2005. View Article : Google Scholar
|
|
4
|
Bensouda Y, Kaikani W, Ahbeddou N, et al:
Treatment for metastatic nasopharyngeal carcinoma. Eur Ann
Otorhinolaryngol Head Neck Dis. 128:79–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Caponigro F, Longo F, Ionna F and Perri F:
Treatment approaches to nasopharyngeal carcinoma: a review.
Anticancer Drugs. 21:471–477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma BB and Chan AT: Systemic treatment
strategies and therapeutic monitoring for advanced nasopharyngeal
carcinoma. Expert Rev Anticancer Ther. 6:383–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaw AT, Yeap BY, Mino-Kenudson M, et al:
Clinical features and outcome of patients with non-small-cell lung
cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Misale S, Yaeger R, Hobor S, et al:
Emergence of KRAS mutations and acquired resistance to anti-EGFR
therapy in colorectal cancer. Nature. 486:532–536. 2012.PubMed/NCBI
|
|
11
|
Bardelli A and Janne PA: The road to
resistance: EGFR mutation and cetuximab. Nat Med. 18:199–200. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Klein G: Nasopharyngeal carcinoma (NPC) is
an enigmatic tumor. Semin Cancer Biol. 12:415–418. 2002.PubMed/NCBI
|
|
13
|
Hui AB, Lo KW, Leung SF, et al: Detection
of recurrent chromosomal gains and losses in primary nasopharyngeal
carcinoma by comparative genomic hybridisation. Int J Cancer.
82:498–503. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fan CS, Wong N, Leung SF, et al: Frequent
c-myc and Int-2 over-representations in nasopharyngeal carcinoma.
Hum Pathol. 31:169–178. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hui AB, Lo KW, Teo PM, To KF and Huang DP:
Genome wide detection of oncogene amplifications in nasopharyngeal
carcinoma by array based comparative genomic hybridization. Int J
Oncol. 20:467–473. 2002.PubMed/NCBI
|
|
16
|
Forbes SA BG, Bamford S, Dawson E, Kok C,
Clements J, Menzies A, Teague JW, Futreal PA and Stratton MR: The
Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum
Genet. Chapter 10:2008.
|
|
17
|
Chou CC, Chou MJ and Tzen CY: PIK3CA
mutation occurs in nasopharyngeal carcinoma but does not
significantly influence the disease-specific survival. Med Oncol.
26:322–326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yip WK, Leong VC, Abdullah MA, Yusoff S
and Seow HF: Overexpression of phospho-Akt correlates with
phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal
carcinoma. Oncol Rep. 19:319–328. 2008.PubMed/NCBI
|
|
19
|
Fendri A, Khabir A, Mnejja W, et al:
PIK3CA amplification is predictive of poor prognosis in Tunisian
patients with nasopharyngeal carcinoma. Cancer Sci. 100:2034–2039.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Naji F, Attaleb M, Laantri N, et al:
Identification of G2607A mutation in EGFR gene with a significative
rate in Moroccan patients with nasopharyngeal carcinoma. Cell Mol
Biol. 56:OL1442–OL1446. 2010.PubMed/NCBI
|
|
21
|
Huang PY, Hong MH, Zhang X, Mai HQ, Luo DH
and Zhang L: C-KIT overexpression and mutation in nasopharyngeal
carcinoma cell lines and reactivity of Imatinib on these cell
lines. Chin J Cancer. 29:131–135. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding L, Getz G, Wheeler DA, et al: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fumagalli D, Gavin PG, Taniyama Y, et al:
A rapid, sensitive, reproducible and cost-effective method for
mutation profiling of colon cancer and metastatic lymph nodes. BMC
Cancer. 10:1012010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu N, Tang LL, Sun Y, et al: MiR-29c
suppresses invasion and metastasis by targeting TIAM1 in
nasopharyngeal carcinoma. Cancer Lett. 329:181–188. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wetterskog D, Lopez-Garcia MA, Lambros MB,
et al: Adenoid cystic carcinomas constitute a genomically distinct
subgroup of triple-negative and basal-like breast cancers. J
Pathol. 226:84–96. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duprez R, Wilkerson PM, Lacroix-Triki M,
et al: Immunophenotypic and genomic characterization of papillary
carcinomas of the breast. J Pathol. 226:427–441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thomas RK, Baker AC, Debiasi RM, et al:
High-throughput oncogene mutation profiling in human cancer. Nat
Genet. 39:347–351. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pearce M, Hogg G, Hosseni D and Ehrich M:
Mutation profiling in tumor samples using the Sequenom OncoCarta™
Panel. Nature Methods. 6:vii–viii. 2009.
|
|
30
|
Jhawer M, Goel S, Wilson AJ, et al: PIK3CA
mutation/PTEN expression status predicts response of colon cancer
cells to the epidermal growth factor receptor inhibitor cetuximab.
Cancer Res. 68:1953–1961. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cappuzzo F, Ciuleanu T, Stelmakh L, et al:
Erlotinib as maintenance treatment in advanced non-small-cell lung
cancer: a multicentre, randomised, placebo-controlled phase 3
study. Lancet Oncology. 11:521–529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tie J, Lipton L, Desai J, et al: KRAS
mutation is associated with lung metastasis in patients with
curatively resected colorectal cancer. Clin Cancer Res.
17:1122–1130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Or YY, Hui AB, To KF, Lam CN and Lo KW:
PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer.
118:1065–1067. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qian CN, Guo X, Cao B, et al: Met protein
expression level correlates with survival in patients with
late-stage nasopharyngeal carcinoma. Cancer Res. 62:589–596.
2002.PubMed/NCBI
|
|
35
|
Forbes SA, Bindal N, Bamford S, et al:
COSMIC: mining complete cancer genomes in the Catalogue of Somatic
Mutations in Cancer. Nucleic Acids Res. 39:D945–D950. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Su KY, Chen HY, Li KC, et al: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA
is implicated as an oncogene in ovarian cancer. Nat Genet.
21:99–102. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang S, Bader AG and Vogt PK:
Phosphatidylinositol 3-kinase mutations identified in human cancer
are oncogenic. Proc Natl Acad Sci USA. 102:802–807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Abers GA, Ferris A, Craig M, et al: Mantle
compensation of active metamorphic core complexes at Woodlark rift
in Papua New Guinea. Nature. 418:862–865. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Qiu FH, Ray P, Brown K, et al: Primary
structure of c-kit: relationship with the CSF-1/PDGF receptor
kinase family - oncogenic activation of v-kit involves deletion of
extracellular domain and C terminus. EMBO J. 7:1003–1011.
1988.PubMed/NCBI
|
|
42
|
Phung B, Sun J, Schepsky A, Steingrimsson
E and Ronnstrand L: C-KIT signaling depends on
microphthalmia-associated transcription factor for effects on cell
proliferation. PLoS One. 6:e240642011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Orfao A, Garcia-Montero AC, Sanchez L and
Escribano L; REMA. Recent advances in the understanding of
mastocytosis: the role of KIT mutations. Br J Haematol. 138:12–30.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nakagomi N and Hirota S:
Juxtamembrane-type c-kit gene mutation found in aggressive systemic
mastocytosis induces imatinib-resistant constitutive KIT
activation. Lab Invest. 87:365–371. 2007.PubMed/NCBI
|
|
45
|
Longley BJ Jr, Metcalfe DD, Tharp M, et
al: Activating and dominant inactivating c-KIT catalytic domain
mutations in distinct clinical forms of human mastocytosis. Proc
Natl Acad Sci USA. 96:1609–1614. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Growney JD, Clark JJ, Adelsperger J, et
al: Activation mutations of human c-KIT resistant to imatinib
mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Blood. 106:721–724. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lennartsson J and Rönnstrand L: Stem cell
factor receptor/c-Kit: from basic science to clinical implications.
Physiol Rev. 92:1619–1649. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ma BB, Lui VW, Poon FF, et al: Preclinical
activity of gefitinib in non-keratinizing nasopharyngeal carcinoma
cell lines and biomarkers of response. Invest New Drugs.
28:326–333. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yasuda H, Kobayashi S and Costa DB: EGFR
exon 20 insertion mutations in non-small-cell lung cancer:
preclinical data and clinical implications. Lancet Oncol.
13:e23–e31. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rane SG, Cosenza SC, Mettus RV and Reddy
EP: Germ line transmission of the Cdk4(R24C) mutation facilitates
tumorigenesis and escape from cellular senescence. Mol Cell Biol.
22:644–656. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vax VV, Bibi R, Diaz-Cano S, et al:
Activating point mutations in cyclin-dependent kinase 4 are not
seen in sporadic pituitary adenomas, insulinomas or Leydig cell
tumours. J Endocrinol. 178:301–310. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Brose MS, Volpe P, Feldman M, et al: BRAF
and RAS mutations in human lung cancer and melanoma. Cancer Res.
62:6997–7000. 2002.PubMed/NCBI
|
|
53
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
